Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium Adolescentis PRL2019 in Pediatric IBS
NCT05737277Unknown
- Sponsor
- Sant'Andrea Hospital
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in irritable bowel syndrome (IBS) comparing GABAPRAL with Placebo (2 arms). Primary endpoint: Change in abdominal pain symptoms (frequency and severity) according to Rome IV criteria at 2 months. Status: unknown.
02
Drugs
Bifidobacterium adolescentis PRL2019
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT05737277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737277.